{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-132299","form_type":"8-K","ticker":"ZYME","cik":"0001937653","company_name":"Zymeworks Inc.","filed_at":"2025-05-30T23:59:59+00:00","discovered_at":"2026-05-14T18:02:50.509387+00:00","generated_at":"2026-05-20T04:58:14.414932+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Zymeworks' zanidatamab wins NMPA conditional approval in China for HER2+ BTC; $20M milestone due","bullets":["NMPA (China) conditionally approved zanidatamab for previously treated unresectable/metastatic HER2+ biliary tract cancer (IHC3+).","Zymeworks receives $20M milestone from BeOne Medicines (formerly BeiGene); already received $61M in prior payments.","Eligible for up to $144M in additional development/commercial milestones and tiered royalties up to 19.5% on net sales.","Approval based on HERIZON-BTC-01 study showing overall survival benefit; confirmatory trials ongoing.","Zanidatamab previously approved by FDA (Nov 2024); EMA CHMP positive opinion (Apr 2025) for same indication."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-132299","json":"https://secwatch.observer/filing/0001193125-25-132299.json","markdown":"https://secwatch.observer/filing/0001193125-25-132299.md","text":"https://secwatch.observer/filing/0001193125-25-132299.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1937653/000119312525132299/0001193125-25-132299-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1937653/000119312525132299/d18018d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-20T04:58:14.414932+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}